| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/20/2009 | CA2373484C Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs |
| 01/20/2009 | CA2366268C Pharmaceutical compositions for cns and other disorders |
| 01/20/2009 | CA2338794C New oral formulation for 5-ht4 agonists or antagonists |
| 01/20/2009 | CA2305621C Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/20/2009 | CA2271693C Guanylhydrazones useful for treating diseases associated with t cell activation |
| 01/20/2009 | CA2261040C Pharmaceutical composition comprising combination useful for treatment or prevention of arteriosclerosis or xanthoma |
| 01/15/2009 | WO2009009561A1 Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| 01/15/2009 | WO2009009004A1 Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations |
| 01/15/2009 | WO2009008992A2 Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 |
| 01/15/2009 | WO2009008511A1 Normal-pressure glaucoma model and method of evaluating test substance by using the same |
| 01/15/2009 | WO2009008176A1 Therapeutic agent for lymphoma |
| 01/15/2009 | WO2009007700A1 Treatment of melanoma |
| 01/15/2009 | WO2009007680A2 Combinations comprising a mast cell inhibitor and a statin for use in the treatment of inflammatory disorders |
| 01/15/2009 | WO2009007674A2 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast |
| 01/15/2009 | WO2009007673A2 Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a ppar gamma agonist |
| 01/15/2009 | WO2008115597A3 Cytokine muteins and methods for enhancing immune responses in mammals |
| 01/15/2009 | WO2008065397A3 Assay |
| 01/15/2009 | US20090018312 Igf-1 receptor interacting proteins |
| 01/15/2009 | US20090018198 Method for treating a motoneuron disorder |
| 01/15/2009 | US20090018164 Farnesyl protein transferase inhibitors for treating breast cancer |
| 01/15/2009 | US20090018137 Buffer intracellular reduction and oxidation for the stressed cells in various disease states; beneficial as adjunctive support therapy, multiple chemical sensitivity syndrome, Charcot-Marie-Tooth disease, Dejerine-Sottas syndrome, Roussy-Levy syndrome, Rosenberg Chutorian syndrome, Korsakoff syndrome |
| 01/15/2009 | US20090018115 Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| 01/15/2009 | US20090018077 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018076 Fibroblast Growth Factor-Like Polypeptides |
| 01/15/2009 | US20090018073 Administering polypeptide of growth factor to increase mitogenesis; bind to receptors and increase cell differentiation and survival |
| 01/15/2009 | US20090018068 G-protein coupled receptors |
| 01/15/2009 | US20090018066 Pharmaceutical compositions for modulating the activity of a novel triglyceride hydrolase |
| 01/15/2009 | US20090018053 Formulations for amylin agonist peptides |
| 01/15/2009 | US20090018052 Treatment of Diabetes and Related Pathologies |
| 01/15/2009 | US20090017559 Methods for diagnosing renal disorders |
| 01/15/2009 | US20090017534 Nucleotide sequences coding voltage-gated transport proteins for use as screening tools to identify modulators for treatment and prevention of nervous, muscular, glandular, immune, reproductive and epithelial tissue disorders |
| 01/15/2009 | US20090017494 Tick octopamine receptor nucleic acid molecules, proteins and uses thereof |
| 01/15/2009 | US20090017121 dispersed in a polymerc matrix comprising swellable hydrophilic polyethylene oxide that swells unrestrained dimensionally by imbibing H2O to increase its size to promote gastric retention of the dosage form in a stomach in fed mode, upon contact with H2O gabapentin released by diffusion; bioavailability |
| 01/15/2009 | US20090017077 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 01/15/2009 | US20090017076 Treatment for cd5+ b cell lymphoma |
| 01/15/2009 | US20090017075 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 01/15/2009 | US20090017018 Uses of mammalian cytokine: related reagents |
| 01/15/2009 | US20090017014 Compositions and methods for the treatment of immune related diseases |
| 01/15/2009 | US20090017002 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes |
| 01/15/2009 | CA2693646A1 Normal-tension glaucoma model and method for evaluation of test substances by using same |
| 01/15/2009 | CA2693628A1 New combination for use in the treatment of imflammatory disorders |
| 01/15/2009 | CA2693400A1 Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| 01/15/2009 | CA2692977A1 Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
| 01/15/2009 | CA2692234A1 Treatment of melanoma |
| 01/15/2009 | CA2691836A1 Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations |
| 01/14/2009 | EP2014770A2 WNT-1 Iinduced secreted polypeptide WISP-2 |
| 01/14/2009 | EP2014677A1 A-33 related antigens and their pharmacological uses |
| 01/14/2009 | EP2014303A2 APO-2L receptor agonist and CPT-11 synergism |
| 01/14/2009 | EP2014300A1 Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene WT1 and a cationic liposome |
| 01/14/2009 | EP2014298A2 Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| 01/14/2009 | EP2014297A1 Control of intracellular target molecule by ip3 receptor-binding protein |
| 01/14/2009 | EP2014282A2 Treatment of depression |
| 01/14/2009 | EP2014180A1 Composition useful for the reduction of the cardivascular risk and foods that contain it |
| 01/14/2009 | EP2012878A2 Combination therapy for diseases involving angiogenesis |
| 01/14/2009 | EP2012828A2 Compositions and methods for the treatment of cardiovascular disease |
| 01/14/2009 | EP2012827A2 Methods of treating, diagnosing or detecting cancer |
| 01/14/2009 | EP2012826A2 Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases |
| 01/14/2009 | EP2012801A2 Gemcitabine combination therapy |
| 01/14/2009 | EP2012787A2 Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| 01/14/2009 | EP2012761A1 Statins for the treatment of viral influenza infections |
| 01/14/2009 | EP2012751A2 Novel nanoparticles for delivery of active agents |
| 01/14/2009 | EP1641443B1 Cosmetic and/or pharmaceutical composition comprising dimthylsulphone and a sunscreen for the cure and prevention of irritation, inflammation and cutaneous erythema |
| 01/14/2009 | EP1487486B1 Imidazoquinolineamines as adjuvants in hiv dna vaccination |
| 01/14/2009 | EP1463728B1 Fused cyclic modulators of nuclear hormone receptor function |
| 01/14/2009 | EP1436291B1 Indolizines as kinase protein inhibitors |
| 01/14/2009 | EP1311241B1 Use of a porous carrier |
| 01/14/2009 | EP1283057B1 Cell proliferation inhibitors |
| 01/14/2009 | EP1233948B1 Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 01/14/2009 | EP1187918B2 Tek antagonists |
| 01/14/2009 | EP1146913B1 Conjugates of granulocyte colony stimulating factors for targeting and imaging infection and inflammation |
| 01/14/2009 | EP1107775B2 Composition containing pyrrolizidine-alkaloid-free petasites |
| 01/14/2009 | CN101343251A Thrombopoietin mimetics |
| 01/14/2009 | CN101343250A Thrombopoietin mimetics |
| 01/14/2009 | CN101342169A Thrombopoietin mimetics |
| 01/14/2009 | CN101342142A Temperature sensing in situ gel rubber formulations capable of being injected, preparation method and uses thereof |
| 01/14/2009 | CN100450550C Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 01/14/2009 | CN100450501C Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases and preparing process thereof |
| 01/14/2009 | CN100450487C Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation |
| 01/14/2009 | CN100450485C 5-HT 1a receptor subtype agonists |
| 01/14/2009 | CN100450477C Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 01/13/2009 | US7476744 Polymorphic crystalline forms of celecoxib |
| 01/13/2009 | US7476742 treatment of disease such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease; e.g. ethyl (5-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethanoate |
| 01/13/2009 | US7476721 Modified cytokines for use in cancer therapy |
| 01/13/2009 | US7476720 Rat neurotrophic factor receptor, GFR α-4 |
| 01/13/2009 | US7476676 Administering to the mammal an effective amount of a GSK-3 beta (glycogen synthase kinase-3 beta) to promote bone formation and treat bone metabolic diseases such as osteoporosis |
| 01/13/2009 | US7476652 by addition of surfactants such as nonionic surfactants of the (poly)ethoxylated fatty acid type; storage stability to hydrophobic aggregation nuclei for several months under temperature stress |
| 01/13/2009 | US7476388 Gastrin, and a second dose of an epithelial growth factor; in vivo islet cell regeneration, preexisting diabetes, islet neogenesis |
| 01/13/2009 | US7476383 Antiproliferative agent; induction apoptosis; antitumor agents |
| 01/13/2009 | US7476380 Using vitamin A and/or the derivatives and/or the esters for therapy and prophylaxis, side effect reduction |
| 01/13/2009 | CA2304704C Formulations and methods for reducing toxicity of antineoplastic agents |
| 01/13/2009 | CA2301032C A method of preventing or treating estrogen-dependent diseases and disorders |
| 01/13/2009 | CA2105534C Tnf ligands |
| 01/08/2009 | WO2009006577A2 Compositions and methods for inhibiting ezh2 |
| 01/08/2009 | WO2009006161A1 Methods and compositions for optimized expansion and implantation of mesenchymal stem cells |
| 01/08/2009 | WO2009006141A2 Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
| 01/08/2009 | WO2009005813A1 Modulators of axl for use in treating bone disorders |
| 01/08/2009 | WO2009005172A1 Pharmaceutical combination of nsaid and prostaglandin compound |
| 01/08/2009 | WO2009005171A1 Pharmaceutical combination of opioid and prostaglandin compound |
| 01/08/2009 | WO2009005142A1 Method for diagnosis of malignancy of gastrointestinal stromal tumor whose primary lesion is in stomach |
| 01/08/2009 | WO2009004995A1 Method of fixing and expressing physiologically active substance |